CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
MK-8457 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01446003
NCT01446003Phase 1Completed

A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients

Merck Sharp & Dohme LLC·interventional·Posted Oct 4, 2011·Updated Feb 5, 2019

In Brief

A Phase 1 clinical trial evaluating MK-8457 and Placebo for MK-8457 for Hypertension. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

This study will evaluate the effect of treatment with multiple doses of MK-8457 on systolic blood pressure in participants with mild to moderate hypertension in addition to safety and tolerability. The study hypothesis is that MK-8457 does not increase systolic blood pressure to a clinically significant extent, as measured by 24-hour mean ambulatory systolic blood pressure change from baseline after 10 days of dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2011
Enrollment StartOct 25, 2011
Primary CompletionFeb 18, 2012
Study CompletionMar 3, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.7 years ago

Interventions

MK-8457drug

10 x 10-mg capsule BID for 10 days

Placebo for MK-8457drug

10 x 10-mg capsule BID for 10 days